Preclinical QT safety assessment: Cross-species comparisons and human translation from an industry consortium
Open Access
- 1 January 2014
- journal article
- research article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 69 (1) , 61-101
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Genome-based analysis of the nonhuman primate Macaca fascicularis as a model for drug safety assessmentGenome Research, 2011
- Dexrazoxane protects the heart from acute doxorubicin‐induced QT prolongation: a key role forIKsBritish Journal of Pharmacology, 2010
- An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing riskBritish Journal of Pharmacology, 2010
- Dose–response effects of sotalol on cardiovascular function in conscious, freely moving cynomolgus monkeysBritish Journal of Pharmacology, 2008
- Principles of Safety PharmacologyBritish Journal of Pharmacology, 2008
- The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correctionBritish Journal of Pharmacology, 2008
- Acute effects of oestrogen on the guinea pig and humanIKrchannels and drug‐induced prolongation of cardiac repolarizationThe Journal of Physiology, 2008
- QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. IIJournal of Applied Toxicology, 2007
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- An improved method to correct the QT interval of the electrocardiogram for changes in heart rateJournal of Pharmacological Methods, 1989